A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Single-Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB054 in Healthy Subjects and Subjects With Early Parkinson's Disease
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2017
At a glance
- Drugs BIIB 054 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Biogen
- 29 Sep 2017 Planned End Date changed from 7 Sep 2017 to 20 Nov 2017.
- 29 Sep 2017 Planned primary completion date changed from 7 Sep 2017 to 20 Nov 2017.
- 29 Sep 2017 Status changed from recruiting to active, no longer recruiting.